Rapid Dose Therapeutics Submits QuickStrip(TM) Nicotine Product for Health Canada Approval

Rhea-AI Summary

Rapid Dose Therapeutics (CSE: DOSE) has submitted its QuickStrip™ Nicotine products for Health Canada approval in multiple dosage formats (1mg, 2mg, 3mg, and 4mg). The product is an innovative oral thin film technology that delivers nicotine through the oral mucosa as a safer alternative to smoking.

The company is currently conducting a pharmacokinetic (PK) clinical trial comparing QuickStrip™ Nicotine to traditional cigarettes. RDT has collaborated with a leading global cigarette manufacturer over the past 30 months and filed two PCT patent applications with partner Aavishkar.

The Canadian nicotine pouches market, valued at $112.2 million in 2024, is projected to grow at 4.7% annually through 2030. This submission follows a previous 2019 application that was interrupted by COVID-19.

Positive

• Development of innovative nicotine delivery system targeting large market opportunity
• Strategic partnership with leading global cigarette manufacturer
• Two international patent applications filed for proprietary technology
• Multiple dosage formats (1-4mg) allowing personalized usage
• Targeting growing nicotine pouches market valued at $112.2M with 4.7% annual growth

Negative

• Previous 2019 Health Canada application was unsuccessful due to COVID-19
• Product still pending regulatory approval and clinical trial results
• Faces competition in established nicotine replacement therapy market

Innovative Oral Nicotine Delivery Technology Targets Safer Alternative for Smokers

Burlington, Ontario--(Newsfile Corp. - August 4, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian life sciences company focused on innovative drug delivery technologies, is pleased to announce the submission of a product application to Health Canada for approval of its QuickStrip™ Nicotine products in 1 mg, 2 mg, 3 mg, and 4 mg formats. This regulatory milestone marks a significant step toward the commercialization of RDT's proprietary oral nicotine delivery system, which has been developed as a safer alternative to smoking.

QuickStrip™ is a fast-dissolving oral thin film that delivers active ingredients directly through the oral mucosa. RDT's NicStrip™ product line leverages this platform to provide nicotine in a controlled, smoke-free format, aimed at helping smokers reduce or quit smoking altogether. The nicotine products are currently undergoing a pharmacokinetic (PK) clinical trial, comparing QuickStrip™ Nicotine to traditional combustible cigarettes in order to evaluate absorption and efficacy.

"We believe this submission represents a critical advancement in our mission to support harm reduction for smokers," said Mark Upsdell, CEO of Rapid Dose Therapeutics. "With millions of Canadians seeking safer nicotine alternatives, QuickStrip™ offers a convenient, discreet, and non-combustible option. Our goal is to empower individuals with effective tools to reduce the health risks associated with smoking."

Over the past 30 months, RDT has worked closely with a leading global cigarette manufacturer to refine the QuickStrip™ Nicotine product in preparation for launch. This strategic partnership has enabled extensive R&D toward product optimization, laying the groundwork for regulatory submission and commercialization. RDT and its production partner Aavishkar have filed two international patent applications under the Patent Cooperation Treaty (PCT), covering advancements in nicotine delivery, film formulation, and controlled-release technology.

The current PK study is being conducted under Good Clinical Practice (GCP) guidelines and is designed to gather detailed data on the bioavailability of nicotine delivered via the QuickStrip™ platform compared to inhaled nicotine from cigarettes. Results will support product claims and regulatory positioning and are a key component of the Health Canada submission.

"Our QuickStrip™ delivery system is designed to mimic the nicotine absorption curve of a cigarette without the harmful by products of combustion," said Jason Lewis, Senior Vice President of RDT. "It provides rapid onset, consistent dosing, and eliminates second-hand smoke-critical attributes for any successful smoking cessation or harm reduction strategy."

The product is intended to be used by adult smokers who are seeking to reduce or quit tobacco use. With the inclusion of multiple dose strengths (1 mg to 4 mg), QuickStrip™ Nicotine allows users to personalize their nicotine intake and taper use over time, supporting individualized usage plans.

Upon regulatory approval, RDT plans to launch the product across Canada and to expand distribution through its commercial partnerships, including potential licensing in other global markets.

"Today's announcement underscores our commitment to innovation and public health," added Lewis. "We're not just developing a product-we're contributing to a movement toward safer alternatives for nicotine users.

Background & Market Opportunity

Rapid Dose Therapeutics previously submitted a nicotine product application to Health Canada in 2019. However, due to the COVID-19 pandemic, the regulatory process could not be completed at that time.

The Canadian nicotine pouches market was valued at USD 112.2 million in 2024, with projected annual growth of 4.7% through 2030, driven by increased adoption of discreet, smoke-free alternatives and a growing public health focus on harm reduction (Grand View Research- Canada Nicotine Pouches Market Report, 2024).

This initiative aligns with the Government of Canada's Tobacco Strategy (CTS), which aims to reduce tobacco use to less than 5% by 2035 (Government of Canada-Canada's Tobacco Strategy), and supports the World Health Organization's goal of reducing adult smoking prevalence by 30% by 2030 as part of the WHO Framework Convention on Tobacco Control (FCTC) (WHO-Global Action Plan for the Prevention and Control of NCDs).

For more information, please contact:

RDT Investor Contact:
Mark Upsdell, CEO
Investorrelations@rapid-dose.com
416-477-1052

About Rapid Dose Therapeutics

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through its proprietary QuickStrip™ technology-a fast-dissolving, thin oral film that offers precise dosing and rapid onset. RDT offers a full-service, turn-key solution for product development, manufacturing, and commercialization of novel oral drug delivery products in both the consumer and pharmaceutical sectors.

Forward-Looking Information

This press release contains forward-looking information within the meaning of applicable Canadian securities legislation. Forward-looking statements include statements related to the approval, efficacy, and commercialization of RDT's QuickStrip™ Nicotine product. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on forward-looking statements. RDT undertakes no obligation to update or revise these statements, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/261147

FAQ

What is Rapid Dose Therapeutics' QuickStrip Nicotine product and how does it work?

QuickStrip Nicotine is a fast-dissolving oral thin film that delivers nicotine directly through the oral mucosa, offering a smoke-free alternative to traditional cigarettes with controlled dosing in 1mg, 2mg, 3mg, and 4mg formats.

When did RDTCF submit its QuickStrip Nicotine product to Health Canada?

Rapid Dose Therapeutics submitted its QuickStrip Nicotine product application to Health Canada on August 4, 2025. This follows a previous submission in 2019 that was interrupted by COVID-19.

What is the market potential for RDTCF's nicotine product in Canada?

The Canadian nicotine pouches market was valued at $112.2 million in 2024 with projected annual growth of 4.7% through 2030, driven by increasing demand for smoke-free alternatives.

What clinical trials is RDTCF conducting for QuickStrip Nicotine?

RDTCF is conducting a pharmacokinetic (PK) clinical trial comparing QuickStrip Nicotine to traditional combustible cigarettes to evaluate absorption and efficacy under Good Clinical Practice guidelines.

Who is RDTCF partnering with for the QuickStrip Nicotine development?

RDTCF has partnered with a leading global cigarette manufacturer for R&D and product optimization, and with Aavishkar for production, filing two international patent applications together.